Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
Connecticut Children's Medical Center · NCT07224113
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 10–21 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- November 10, 2025
- Record last updated
- July 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study explores whether simple nutrition education can help children and teens with inflammatory bowel disease (IBD) eat fewer ultra-processed foods (UPFs). UPFs include packaged snacks, sugary drinks, and fast food-items that are high in added sugars, fats, and artificial ingredients. Participants will complete online food recalls to measure what they eat and will then receive either nutrition handouts alone or handouts plus a short educational video about UPFs. Researchers will compare changes in UPF intake between the two groups after several weeks and ask families how useful and acceptable they found the materials. The goal is to identify an effective, practical way to support healthier eating habits and long-term gut health in pediatric IBD.
Being studied: Handout-Only Intervention; Handout + Video Intervention
Conditions: IBD; Crohn Disease (CD); Ulcerative Colitis (UC); Inflammatory Bowel Disease (IBD); Ultra Processed Food; Nutrition Assessment; DGBI
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Diagnosis of IBD (Crohn's disease, Ulcerative Colitis, IBD-U) for at least 3 months
- Age 10 through \< 22 years at the time of enrollment (i.e., up to the day before the 22nd birthday)
- Followed by a gastroenterologist at Connecticut Children's
- IBD in clinical remission based on calculated PUCAI score \<10 or PCDAI score of \<10
- Receiving medical infusions at CCMC Infusion Center as part of IBD treatment
- Participants must be on full oral intake and not have major dietary restrictions or require oral nutrition supplements
Exclusion Criteria
- Following a medically prescribed or restrictive diet such as Crohn's Disease Exclusion Diet (CDED), ketogenic diet, Specific Carbohydrate Diet (SCD), low FODMAP diet, gluten-free diet, paleo, or Whole30.
- Receiving any nutrition through feeding tubes (including nasogastric [NG], nasojejunal [NJ], gastrostomy [G], or gastrojejunostomy [GJ] tubes)
- History of bowel surgery within 3 months of study start affecting ability to sustain normal enteral intake
- Non-English-speaking participants (as translation and short-form consent processes will not be used for this study)
Recruiting US locations
Connecticut Children's Medical Center
Hartford, CT 06106
Site contact: Giselle Davila-Bernardy, MD · 8605459560 · gdavilabernardy@connecticutchildrens.org
Study contacts (from the official record)
- Giselle M Davila Bernardy, MD · 8605459560 · gdavilabernardy@connecticutchildrens.org
Similar studies in Connecticut
All nutrition & metabolism studies in Connecticut →- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- New Haven, CT + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim
- Location
- Bristol, CT + 154 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim
- Location
- Bristol, CT + 123 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc
- Location
- New Haven, CT + 130 other US sites
- Eligibility basics
- Ages 18–80